Your browser doesn't support javascript.
loading
Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources.
Köhler, Sebastian; Carmody, Leigh; Vasilevsky, Nicole; Jacobsen, Julius O B; Danis, Daniel; Gourdine, Jean-Philippe; Gargano, Michael; Harris, Nomi L; Matentzoglu, Nicolas; McMurry, Julie A; Osumi-Sutherland, David; Cipriani, Valentina; Balhoff, James P; Conlin, Tom; Blau, Hannah; Baynam, Gareth; Palmer, Richard; Gratian, Dylan; Dawkins, Hugh; Segal, Michael; Jansen, Anna C; Muaz, Ahmed; Chang, Willie H; Bergerson, Jenna; Laulederkind, Stanley J F; Yüksel, Zafer; Beltran, Sergi; Freeman, Alexandra F; Sergouniotis, Panagiotis I; Durkin, Daniel; Storm, Andrea L; Hanauer, Marc; Brudno, Michael; Bello, Susan M; Sincan, Murat; Rageth, Kayli; Wheeler, Matthew T; Oegema, Renske; Lourghi, Halima; Della Rocca, Maria G; Thompson, Rachel; Castellanos, Francisco; Priest, James; Cunningham-Rundles, Charlotte; Hegde, Ayushi; Lovering, Ruth C; Hajek, Catherine; Olry, Annie; Notarangelo, Luigi; Similuk, Morgan.
Afiliação
  • Köhler S; Charité Centrum für Therapieforschung, Charité-Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin 10117, Germany.
  • Carmody L; Einstein Center Digital Future, Berlin 10117, Germany.
  • Vasilevsky N; Monarch Initiative, monarchinitiative.org.
  • Jacobsen JOB; Monarch Initiative, monarchinitiative.org.
  • Danis D; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
  • Gourdine JP; Monarch Initiative, monarchinitiative.org.
  • Gargano M; Oregon Health & Science University, Portland, OR 97217, USA.
  • Harris NL; Monarch Initiative, monarchinitiative.org.
  • Matentzoglu N; Genomics England, Queen Mary University of London, Dawson Hall, Charterhouse Square, London EC1M 6BQ, UK.
  • McMurry JA; Monarch Initiative, monarchinitiative.org.
  • Osumi-Sutherland D; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
  • Cipriani V; Monarch Initiative, monarchinitiative.org.
  • Balhoff JP; Oregon Health & Science University, Portland, OR 97217, USA.
  • Conlin T; Monarch Initiative, monarchinitiative.org.
  • Blau H; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
  • Baynam G; Monarch Initiative, monarchinitiative.org.
  • Palmer R; Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
  • Gratian D; Monarch Initiative, monarchinitiative.org.
  • Dawkins H; European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.
  • Segal M; Monarch Initiative, monarchinitiative.org.
  • Jansen AC; Linus Pauling institute, Oregon State University, Corvallis, OR, USA.
  • Muaz A; Monarch Initiative, monarchinitiative.org.
  • Chang WH; European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.
  • Bergerson J; Monarch Initiative, monarchinitiative.org.
  • Laulederkind SJF; William Harvey Research Institute, Queen Mary University College of London.
  • Yüksel Z; UCL Genetics Institute, University College of London.
  • Beltran S; UCL Institute of Ophthalmology, University College of London.
  • Freeman AF; Monarch Initiative, monarchinitiative.org.
  • Sergouniotis PI; Renaissance Computing Institute, University of North Carolina at Chapel Hill.
  • Durkin D; Monarch Initiative, monarchinitiative.org.
  • Storm AL; Linus Pauling institute, Oregon State University, Corvallis, OR, USA.
  • Hanauer M; Monarch Initiative, monarchinitiative.org.
  • Brudno M; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
  • Bello SM; Western Australian Register of Developmental Anomalies and Genetic Services of Western Australia, Department of Health, Government of Western Australia, WA, Australia.
  • Sincan M; School of Paediatrics and Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
  • Rageth K; Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
  • Wheeler MT; Spatial Sciences, Department of Science and Engineering, Curtin University, Perth, WA, Australia.
  • Oegema R; The Office of Population Health Genomics, Department of Health, Government of Western Australia, Perth, WA, Australia.
  • Lourghi H; Spatial Sciences, Department of Science and Engineering, Curtin University, Perth, WA, Australia.
  • Della Rocca MG; Western Australian Register of Developmental Anomalies and Genetic Services of Western Australia, Department of Health, Government of Western Australia, WA, Australia.
  • Thompson R; The Office of Population Health Genomics, Department of Health, Government of Western Australia, Perth, WA, Australia.
  • Castellanos F; SimulConsult, Chestnut Hill, MA, USA.
  • Priest J; Neurogenetics Research Group, Vrije Universiteit Brussel, Brussels, Belgium.
  • Cunningham-Rundles C; Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel, Brussels, Belgium.
  • Hegde A; Monarch Initiative, monarchinitiative.org.
  • Lovering RC; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW 2010, Australia.
  • Hajek C; Centre for Computational Medicine, Hospital for Sick Children and Department of Computer Science, University of Toronto, Toronto, Canada.
  • Olry A; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Notarangelo L; Rat Genome Database, Department of Biomedical Engineering, Medical College of Wisconsin & Marquette University, 8701 Watertown Plank Road Milwaukee, WI 53226, USA.
  • Similuk M; Bioscientia GmbH, Ingelheim, Germany.
Nucleic Acids Res ; 47(D1): D1018-D1027, 2019 01 08.
Article em En | MEDLINE | ID: mdl-30476213
ABSTRACT
The Human Phenotype Ontology (HPO)-a standardized vocabulary of phenotypic abnormalities associated with 7000+ diseases-is used by thousands of researchers, clinicians, informaticians and electronic health record systems around the world. Its detailed descriptions of clinical abnormalities and computable disease definitions have made HPO the de facto standard for deep phenotyping in the field of rare disease. The HPO's interoperability with other ontologies has enabled it to be used to improve diagnostic accuracy by incorporating model organism data. It also plays a key role in the popular Exomiser tool, which identifies potential disease-causing variants from whole-exome or whole-genome sequencing data. Since the HPO was first introduced in 2008, its users have become both more numerous and more diverse. To meet these emerging needs, the project has added new content, language translations, mappings and computational tooling, as well as integrations with external community data. The HPO continues to collaborate with clinical adopters to improve specific areas of the ontology and extend standardized disease descriptions. The newly redesigned HPO website (www.human-phenotype-ontology.org) simplifies browsing terms and exploring clinical features, diseases, and human genes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_sistemas_informacao_saude Assunto principal: Anormalidades Congênitas / Biologia Computacional / Predisposição Genética para Doença / Doenças Raras / Bases de Conhecimento / Ontologias Biológicas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Nucleic Acids Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_sistemas_informacao_saude Assunto principal: Anormalidades Congênitas / Biologia Computacional / Predisposição Genética para Doença / Doenças Raras / Bases de Conhecimento / Ontologias Biológicas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Nucleic Acids Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha
...